Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Gilead Sciences,Sofosbuvir with velpatasvir and voxilaprevir,"Hepatitis C, second-line after prior direct-acting antiviral treatment, NS5A resistance",Sofosbuvir with velpatasvir and voxilaprevir (Vosevi),Only if cost neutral or cost saving,Community and Hospital,Infections - Agents for Systemic Use
